Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash & Current Investments: 2016-2024

Historic Cash & Current Investments for Dianthus Therapeutics (DNTH) over the last 7 years, with Dec 2024 value amounting to $275.2 million.

  • Dianthus Therapeutics' Cash & Current Investments rose 43.22% to $402.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 0.49%. This contributed to the annual value of $275.2 million for FY2024, which is 58.44% up from last year.
  • Latest data reveals that Dianthus Therapeutics reported Cash & Current Investments of $275.2 million as of FY2024, which was up 58.44% from $173.7 million recorded in FY2023.
  • In the past 5 years, Dianthus Therapeutics' Cash & Current Investments registered a high of $275.2 million during FY2024, and its lowest value of $75.5 million during FY2022.
  • For the 3-year period, Dianthus Therapeutics' Cash & Current Investments averaged around $174.8 million, with its median value being $173.7 million (2023).
  • Data for Dianthus Therapeutics' Cash & Current Investments shows a peak YoY spiked of 130.12% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Dianthus Therapeutics' Cash & Current Investments stood at $75.5 million in 2022, then soared by 130.12% to $173.7 million in 2023, then spiked by 58.44% to $275.2 million in 2024.